Equity Coverage on Biotechnology -- Aeterna Zentaris, Ariad Pharma, AVEO Pharma, Aduro BioTech, and 22nd Century Group

Jul 16, 2015, 09:10 ET from www.equityresearchinstitute.com

NEW YORK, July 16, 2015 /PRNewswire/ --

Equity Research Institute has initiated coverage on the following equities: Aeterna Zentaris Inc. (NASDAQ: AEZS), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), AVEO Pharmaceuticals Inc. (NASDAQ: AVEO), Aduro BioTech Inc. (NASDAQ: ADRO), and 22nd Century Group Inc. (AMEX: XXII). Free research report on Aeterna Zentaris can be accessed at https://www.EquityResearchInstitute.com/reports?keyword=AEZS On Wednesday, July 15, 2015, the NASDAQ Composite ended at 5,098.94, down 0.12%, the Dow Jones Industrial Average edged 0.02% lower, to finish the day at 18,050.17, and the S&P 500 closed at 2,107.40, down 0.07%. The losses were broad based as six out of nine sectors ended the session in negative. Register for your complimentary reports at the links given below.  

On Wednesday, shares in Aeterna Zentaris Inc. recorded a trading volume of 3.30 million shares, lower than their three months average volume of 3.96 million shares. The stock ended the day 4.20% lower at $0.23. Aeterna Zentaris Inc.'s stock has lost 20.05% in the last one month, 64.08% in the previous three months and 61.98% on YTD basis. The company is trading below its 50-day and 200-day moving averages by 29.57% and 62.46%, respectively. Furthermore, shares of Aeterna Zentaris Inc. have a Relative Strength Index (RSI) of 26.42. Sign up and read the free notes on AEZS at:

https://www.EquityResearchInstitute.com/reports?keyword=AEZS

Ariad Pharmaceuticals Inc.'s stock declined 1.65%, to close Wednesday's session at $8.35. The stock recorded a trading volume of 3.72 million shares, below its three months average volume of 3.83 million shares. Over the last one month and the previous three months, Ariad Pharmaceuticals Inc.'s shares have lost 2.34% and 6.49%, respectively. However, the stock has gained 21.54% on YTD basis. The company is trading 11.57% above its 200-day moving average. Furthermore, Ariad Pharmaceuticals Inc.'s stock has an RSI of 50.19. The complimentary notes on ARIA can be downloaded in PDF format at:

https://www.EquityResearchInstitute.com/reports?keyword=ARIA

AVEO Pharmaceuticals Inc.'s stock finished Wednesday's session 3.13% lower at $1.55. A total of 0.59 million shares were traded, which was much below its three months average volume of 3.87 million shares. Over the previous three months and since the beginning of 2015, AVEO Pharmaceuticals Inc.'s shares have surged 4.73% and 84.52%, respectively. However, the stock has lost 23.27% in the last one month. The company's shares are trading above their 200-day moving average by 20.81%. AVEO Pharmaceuticals Inc.'s stock has an RSI of 43.82. Register for free on Equity Research Institute and access the latest research on AVEO at:

https://www.EquityResearchInstitute.com/reports?keyword=AVEO

On Wednesday, shares in Aduro BioTech Inc. ended the session 0.36% higher at $30.95. The stock reported a trading volume of 0.14 million shares, below its three months average volume of 0.55 million shares. Aduro BioTech Inc.'s shares have declined 14.03% in the last one month, 26.31% in the previous three months and 26.31% on YTD basis. The company is trading 3.77% below its 50-day moving average and 5.37% below its 200-day moving average. Moreover, shares of Aduro BioTech Inc. have an RSI of 44.79. The complete research on ADRO is available for free at:

https://www.EquityResearchInstitute.com/reports?keyword=ADRO

22nd Century Group Inc.'s stock lost 3.91%, to close the day at $0.81. The stock recorded a trading volume of 0.33 million shares, below its three months average volume of 0.56 million shares. Over the last one month and the past three months, 22nd Century Group Inc.'s shares have declined 11.95% and 2.39%, respectively. Furthermore, the stock has lost 50.91% since the start of this year. The company's shares are trading 18.49% below their 50-day moving average and 41.19% below their 200-day moving average. Additionally, 22nd Century Group Inc. has an RSI of 37.39. Free in-depth research on XXII is available at:

https://www.EquityResearchInstitute.com/reports?keyword=XXII

--

About Equity Research Institute: 

Equity Research Institute ("ERI") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ERI has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

ERI has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:  

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the CFA® have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the CFA® (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.

NO WARRANTY 

ERI, the Author, the Reviewer and the CFA® (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING 

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ERI nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit www.equityresearchinstitute.com.

RESTRICTIONS 

ERI is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at) equityresearchinstitute.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE www.equityresearchinstitute.com